Posted by Michael Wonder on 30 Nov 2020
Zymeworks receives FDA breakthrough therapy designation for HER2-targeted bispecific antibody zanidatamab in patients with biliary tract cancer
30 November 2020 - Zymeworks today announced that the U.S. FDA has granted breakthrough therapy designation for zanidatamab in patients with previously-treated HER2 gene amplified biliary tract cancer.
Earlier this year, Zymeworks initiated a global Phase 2b registration enabling study of single agent zanidatamab in patients with previously treated HER2 gene amplified biliary tract cancer.
